Clinical Trials Logo

Clinical Trial Summary

Brugada syndrome is an inherited arrhythmia syndrome with an increased risk of syncope and sudden death resulting from episodes of polymorphic ventricular tachychardia and fibrillation. Currently, there is no medical therapy for the Brugada syndrome and the only treatment available is the implantation of an ICD. There is no discussion on the interest of the ICD implantation in secondary prevention and in patients who experienced syncope but the best therapeutic is more difficult to draw in asymptomatic patients. Recently we demonstrated that in asymptomatic patients with a spontaneous type 1 aspect of Brugada syndrome, (i) there was a significant risk of ventricular arrhythmia, (ii) the problem of inappropriate shocks can be solve with a good ICD programming and (iii) the problem of lead failure remains the main problem in this young population very active and represent the main limitation to larger indication of ICD implantation in this population with a very long life expectancy as these patients had a normal life expectancy except the risk of ventricular arrhythmia.

In this context the S-ICD System (Boston Scientific Inc.) which is an implantable defibrillator technology that treats ventricular tachyarrhythmias using a subcutaneous pulse generator and electrode system rather than a transvenous lead system, represents a very attractive opportunity as it gives the possibility to protect the patients of the risk of ventricular arrhythmia with no risk of lead failure. However, as this is a new technology and as Brugada syndrome patients are a very specific population (very active patients, specific and changing over time ECG aspect that is at risk of T wave over sensing and high risk of SVT), it seems important to evaluate the effectiveness and the safety of S-ICD in this specific context.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02344277
Study type Observational
Source Nantes University Hospital
Contact
Status Completed
Phase
Start date May 12, 2015
Completion date April 25, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05048602 - Drug-induced Brugada Syndrome Research Database
Terminated NCT00701077 - DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome Phase 3
Recruiting NCT03435393 - Ripple Mapping for Epicardial Mapping of Brugada Syndrome N/A
Active, not recruiting NCT02933437 - The Response To Ajmaline Provocation in Healthy Subjects Phase 2
Active, not recruiting NCT04257994 - Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Recruiting NCT05685134 - Invasive and Clinical Features in Patients With Brugada Syndrome Undergoing Catheter Ablation N/A
Recruiting NCT04580992 - Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial
Completed NCT02641431 - Epicardial Ablation in Brugada Syndrome N/A
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Completed NCT04124237 - Long Term Monitoring for Risk of Sudden Death
Completed NCT04650009 - Physical Activity in Children With Inherited Cardiac Diseases
Recruiting NCT04808193 - European Perioperative Brugada Survey N/A
Recruiting NCT03491475 - Echocardiography During Ajmaline Test
Recruiting NCT05521451 - Clinical Cohort Study - TRUST
Recruiting NCT03485508 - The Brugada Syndrome: a Follow-up Study
Completed NCT00702117 - Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Phase 4
Recruiting NCT02704416 - Ablation in Brugada Syndrome for the Prevention of VF N/A
Recruiting NCT03775954 - Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
Completed NCT04420078 - Brugada Ablation of VF Substrate Ongoing MultiCenter Registry